## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `semaglutide-statins`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/semaglutide-statins/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/semaglutide-statins/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/semaglutide-statins/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/semaglutide-statins/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/semaglutide-statins/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/semaglutide-statins/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `semaglutide-statins` v5 · content_hash `dcd6b7bdb3704e6e…` · thread_head genesis · 2 DIVs
- **thesis (c1):** 2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.
  - c2 [human/active] Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholester
  - c4 [human/active] 2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.
  - c5 [human/active] 2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.
  - c6 [human/active] 2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).
  - c7 [human/active] Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.
  - c8 [human/active] Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.
  - c9 [human/active] Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/semaglutide-statins/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/semaglutide-statins/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `semaglutide-statins`
- **title:** semaglutide statins
- **url:** https://miscsubjects.com/a/semaglutide-statins
- **register:** standard
- **updated:** 2026-07-17T02:41:49.415Z

## Body

## Overview
Evidence is being populated by Grok web search.

## Claims (10)

- **c1** [human w=0.8] 2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.
  - who_claims: grok-4.3
  - slot: what_is_known
  - sources: s1
- **c2** [human w=0.8] Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholesterolemia.
  - who_claims: grok-4.3
  - slot: what_is_known
  - sources: s2
- **c4** [human w=0.8] 2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.
  - who_claims: grok-4.3
  - slot: what_is_known
  - sources: s4
- **c7** [human w=0.8] Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.
  - who_claims: grok-4.3
  - slot: what_is_known
  - sources: s7
- **c8** [human w=0.8] Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.
  - who_claims: grok-4.3
  - slot: what_is_known
  - sources: s8
- **c9** [human w=0.8] Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.
  - who_claims: grok-4.3
  - slot: what_is_known
  - sources: s9
- **c_map_semaglutide-statins** [runtime w=0.35] Combinatorial mapping (transparent): semaglutide vs statins — regen=0.32, degen=0.45, Δ=-0.13. Method: layer_relevance(0.60) × evidence_factor(0.40); catalog.degen_score for Statins.
- **c3** [mechanistic w=0.3] Preclinical study developing and evaluating nanoparticles combining semaglutide and a statin-lipid conjugate for potential co-delivery.
  - who_claims: grok-4.3
  - slot: what_is_known
  - sources: s3
- **c5** [human w=0.8] 2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.
  - who_claims: grok-4.3
  - slot: what_is_known
  - sources: s5
- **c6** [human w=0.8] 2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).
  - who_claims: grok-4.3
  - slot: what_is_known
  - sources: s6

## Voxel graph (10 atoms · 18 edges)
- full graph: https://miscsubjects.com/api/articles/semaglutide-statins/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (9)
- chain valid: yes · head: `47911d0481591ba3`

### s1 · medical · ok
- title: Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11954779/
- summary: 2025 single-center before-after study (N=41) of patients with IHD on statins starting oral semaglutide for T2D showed significant reduction in RLP cholesterol (8.52 to 5.46 mg/dL, P<0.001) independent of weight loss; also reduced in subgroups on SGLT2i or switching from DPP4i.
- quote: Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.
- claim_ids: c1
- hash: `07e650f34f3ff9c3`

### s2 · pubmed · ok
- title: Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab
- url: https://pubmed.ncbi.nlm.nih.gov/40866272/
- summary: Case report showing oral semaglutide further lowered LDL-C in a patient already on maximal statin-based therapy plus PCSK9 inhibitor for familial hypercholesterolemia.
- quote: We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.
- claim_ids: c2
- hash: `e2c0d2975e46dbb1`

### s3 · pubmed · ok
- title: Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin-Lipid Conjugate Nanoparticles
- url: https://pubmed.ncbi.nlm.nih.gov/40284475/
- summary: Preclinical study developing and evaluating nanoparticles combining semaglutide and a statin-lipid conjugate for potential co-delivery.
- quote: The statin-lipid conjugate was successfully synthesized, forming novel nanoparticles with semaglutide in an aqueous solution.
- claim_ids: c3
- hash: `fd7943666a0523bb`

### s4 · pubmed · ok
- title: Effect of oral semaglutide on remnant-like lipoprotein cholesterol levels in patients with ischemic heart disease receiving statin therapy
- url: https://pubmed.ncbi.nlm.nih.gov/40166440/
- summary: 2025 study showing oral semaglutide further lowers remnant-like lipoprotein cholesterol in statin-treated ischemic heart disease patients.
- quote: Oral semaglutide significantly reduced RLP cholesterol levels in patients with ischemic heart disease who were receiving statin therapy.
- claim_ids: c4
- hash: `cd5f3279adf9bf57`

### s5 · review · ok
- title: Cardiovascular benefits of semaglutide: a systematic review and meta-analysis
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12752371/
- summary: 2025 systematic review/meta-analysis on semaglutide's CV benefits, relevant in context of statin background therapy in related trials.
- quote: This systematic review and meta-analysis demonstrates that semaglutide reduces the risk of major adverse cardiovascular events, cardiovascular mortality, and ...
- claim_ids: c5
- hash: `59488764d2ab2da2`

### s6 · review · ok
- title: Cardiovascular outcomes of semaglutide and tirzepatide for ...
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12823426/
- summary: 2025 review comparing CV outcomes of semaglutide (often on background statins in such populations).
- quote: Relevant for clinical practice, our findings show that treatment with semaglutide lowered the risk of MACE compared to sitagliptin, while tirzepatide showed at ...
- claim_ids: c6
- hash: `bbe408d9ac9a029c`

### s7 · pubmed · ok
- title: Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC13106759/
- summary: Case report of additional LDL-C reduction with oral semaglutide in a patient already on intensive statin-based therapy.
- quote: We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.
- claim_ids: c7
- hash: `2c17393959188982`

### s8 · pubmed · ok
- title: Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12144549/
- summary: Prespecified analysis of SOUL trial showing high baseline statin use (over 84-91%) alongside oral semaglutide in T2D patients with CV risk.
- quote: Concomitant use of beta-blockers (68.9% versus 62.6%), statins (91.2% versus 84.3%), and platelet aggregation inhibitors (81.2% versus 75.7%) was slightly higher in those using SGLT2i at baseline
- claim_ids: c8
- hash: `51d44659e7461715`

### s9 · pubmed · ok
- title: Oral Semaglutide and Change in Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC13019341/
- summary: Post hoc analysis of SOUL trial confirming high concomitant statin use (>80%) with oral semaglutide and effects on CV risk factors.
- quote: For example, statins were used in more than 80% of enrolled participants
- claim_ids: c9
- hash: `47911d0481591ba3`

## Provenance (6 model passes)
- chain valid: yes · head: `b544ec6063a65678`

- populate-init · grok-4.3 · 2026-06-29T18:00 · hash `bccbd81eeeb1`
- sources · grok-4.3 · 2026-06-29T18:00 · hash `800a1a822d0c`
- sources · grok-4.3 · 2026-06-29T18:00 · hash `81c6aed24ea0`
- sources · grok-4.3 · 2026-06-29T18:01 · hash `d5fc60ed11f9`
- sources · grok-4.3 · 2026-06-29T18:01 · hash `67e6e929f2d3`
- voxel_divide · owner · 2026-07-17T02:41 · hash `b544ec6063a6`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/semaglutide-statins/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/semaglutide-statins/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"semaglutide-statins","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest semaglutide-statins|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim semaglutide-statins|tier|assertion`
- **iMessage ask:** `semaglutide-statins|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `semaglutide-statins`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/semaglutide-statins/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/semaglutide-statins/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*